Commvault Systems Inc vs Recursion Pharmaceuticals Inc — how do they compare? Commvault Systems Inc trades at $139 (market cap $5.78B), while Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B). The key difference: Commvault Systems Inc is far larger — about 3.2× Recursion Pharmaceuticals Inc's market cap, and Commvault Systems Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CVLT | RXRX | |
|---|---|---|
Market Cap | $5.78B | $1.81B |
Sector | Technology | Health |
52-Week High | $195.41 | $6.79 |
52-Week Low | $75.18 | $2.84 |
Enterprise Value | $5.76B | $1.33B |
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $139.36, down slightly by 0.05% on the day, with strong technical momentum showing a bullish moving average signal. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $1.42 surpassing the $1.16 estimate. Recent positive developments include the integration of Threat Scan with Google Threat Intelligence and a partnership with Microsoft for AI security on Azure, driving investor optimism despite a shareholder investigation announcement.
CVLT presents a mixed fundamental picture with robust revenue growth and strong profitability metrics but elevated valuation multiples. The stock offers significant upside to the consensus price target of $172.40, supported by 54.5% analyst buy ratings. Key risks include high P/E ratio of 89.35, ongoing fiduciary investigation, and potential margin compression as revenue growth outpaces net income growth in 2026 projections.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Trailing returns across standard periods
Latest headlines on both assets
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →